Compare POAI & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POAI | EVAX |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 42.7M |
| IPO Year | N/A | 2021 |
| Metric | POAI | EVAX |
|---|---|---|
| Price | $5.95 | $5.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | 42.7K | ★ 98.3K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,664,407.00 | ★ $7,650,000.00 |
| Revenue This Year | $486.27 | $128.77 |
| Revenue Next Year | $65.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 320.71 | 132.17 |
| 52 Week Low | $3.88 | $1.20 |
| 52 Week High | $45.90 | $12.15 |
| Indicator | POAI | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 49.31 |
| Support Level | $3.88 | $5.72 |
| Resistance Level | $6.25 | $6.70 |
| Average True Range (ATR) | 0.76 | 0.48 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 79.01 | 38.10 |
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.